CDMOs Step Up to the COVID Challenge but Must Prepare for Uncertain Future
06/11/20 • 12 min
In this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- The CDMO industry in the wake of COVID-19
- Near-term outlook
- Medium-term could be challenging
- Longer-term implications
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
In this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- The CDMO industry in the wake of COVID-19
- Near-term outlook
- Medium-term could be challenging
- Longer-term implications
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Previous Episode
Tracking Expansion in High-Potency Manufacturing
In this podcast, we round up key recent expansions in high-potency manufacturing by CDMOs and CMOs. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Expansions in high-potency manufacturing
- Lonza
- WuXi AppTec
- Seqens
- Cambrex
- Piramal Pharma Solutions
- CordenPharma
- Flamma
- Cerbios-Pharma
- Evonik
- AGC
- Novasep
- Ajinomoto Bio-Pharma Services
- BSP Pharmaceuticals
- PCI Pharma Services
- Sterling Pharma Solutions
- Heraeus
- Procos
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Next Episode
A Top 10 Emerging Pharma Watch List
In this podcast we feature DCAT Value Chain Insights’ Top 10 Emerging Pharma Watch List based on recent high-value partnering deals. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Emerging pharma strength
- 1. Roivant Sciences
- 2. Sangamo Therapeutics
- 3. Silence Therapeutics
- 4. Innovent Biologics
- 5. Arcus Biosciences
- 6. MorphoSys
- 7. Evox Therapeutics
- 8. Accent Therapeutics
- 9. Enleofen Bio
- 10. Sitryx
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/dcat-value-chain-insights-production-to-prescription-649633/cdmos-step-up-to-the-covid-challenge-but-must-prepare-for-uncertain-fu-85679254"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to cdmos step up to the covid challenge but must prepare for uncertain future on goodpods" style="width: 225px" /> </a>
Copy